Program - Society of Toxicology
Program - Society of Toxicology
Program - Society of Toxicology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
50 th Anniversary Annual Meeting and ToxExpo<br />
<strong>Program</strong> Description (Continued)<br />
MONday<br />
Abstract # Abstract #<br />
#142 Poster Board Number.....................................231<br />
EFFECTS OF GENETIC VARIATION IN<br />
ENZYME CYTOCHROME P450 2D6 ON<br />
XENOBIOTIC METABOLISM THROUGH IN<br />
SILICO MOLECULAR DOCKING MODELS. <br />
C. B. Tolson 1,2 , Y. Tie 1 and E. Demchuk 1 . 1 Division<br />
<strong>Toxicology</strong> & Environmental Medicine, ATSDR/<br />
CDC, Atlanta, GA and 2 Biomedical Engineering,<br />
Georgia Institute <strong>of</strong> Technology, Atlanta, GA.<br />
Sponsor: B. Fowler.<br />
#143 Poster Board Number.....................................232<br />
INCORPORATION OF TOXCAST IN VITRO<br />
ASSAY DATA AND RELEVANT TOXICITY<br />
PATHWAY INFORMATION IMPROVES THE<br />
EXTERNAL PREDICTION ACCURACY OF<br />
QUANTITATIVE STRUCTURE-ACTIVITY<br />
RELATIONSHIP (QSAR) MODELS OF<br />
CHEMICAL HEPATOTOXICITY. H. Zhu, L.<br />
Zhang, J. Staab, A. Sedykh, H. Tang, S. Gomez, I.<br />
Rusyn and A. Tropsha. University <strong>of</strong> North Carolina<br />
at Chapel Hill, Chapel Hill, NC.<br />
#144 Poster Board Number.....................................233<br />
COMPUTATIONAL DOCKING OF THE<br />
ISOMERS OF NONYLPHENOL TO THE<br />
LIGAND BINDING DOMAIN OF THE<br />
ESTROGEN RECEPTOR. J. Rabinowitz and S.<br />
Little. NCCT/ORD /U.S. EPA, Research Triangle<br />
Park, NC.<br />
#145 Poster Board Number.....................................234<br />
ANALYSIS OF RELATIVE<br />
ROSIGLITAZONE, PIOGLITAZONE, AND<br />
EPIRUBICIN CARDIOTOXICITY IN RATS<br />
USING HISTORICAL MICROARRAY DATA. <br />
H. Zhou and T. J. Colatsky. CDER/OPS/OTR/DAPR,<br />
U.S. FDA, Silver Spring, MD.<br />
#146 Poster Board Number.....................................235<br />
COMPUTATIONAL MODELING<br />
FOR QT PROLONGATION: A DRUG<br />
CARDIOVASCULAR SAFETY ENDPOINT OF<br />
PARAMOUNT IMPORTANCE. L. G. Valerio 1 ,<br />
J. Prous Blancafort 2 , A. Valencia 2 and X. Mensa 2 .<br />
1<br />
CDER/OPS, U.S. FDA, Silver Spring, MD and<br />
2<br />
Prous Institute for Biomedical Research, Barcelona,<br />
Spain. Sponsor: N. Sadrieh.<br />
#147 Poster Board Number.....................................236<br />
TRANSLATABILITY OF DRUG-INDUCED<br />
CARDIOTOXICITY MOLECULAR<br />
MECHANISMS FROM IN VIVO TO IN<br />
VITRO. A. Enayetallah 1 , D. Puppala 1 , D. Ziemek 2 ,<br />
N. Greene 1 , Y. Will 1 and M. Pletcher 1 . 1 Compound<br />
Safety Prediction-PGRD, Pfizer Inc., Groton, CT<br />
and 2 Computational Sciences CoE, Pfizer Inc.,<br />
Cambridge, MA.<br />
#148 Poster Board Number.....................................237<br />
ASSOCIATION NETWORKS AND<br />
VISUALIZATION TOOLS TO CORRELATE<br />
PRECLINICAL SIGNALS TO DRUG-<br />
INDUCED NAUSEA IN MAN. J. Glab 1 ,<br />
M. Clark 2 , J. Valentin 1 and L. Ewart 1 . 1 Safety<br />
Pharmacology, AstraZeneca, Alderley Park, United<br />
Kingdom and 2 Discovery Information, AstraZeneca,<br />
Wilmington, DE.<br />
#149 Poster Board Number.....................................238<br />
DDT AND TCDD INTERACT WITH<br />
PROTEINS INVOLVED IN THE INSULIN<br />
RECEPTOR SIGNALING. M. Cabarcas-<br />
Montalvo, D. Montes-Grajales and J. Olivero-Verbel.<br />
Environmental and Computational Chemistry Group,<br />
University <strong>of</strong> Cartagena, Cartagena, Colombia.<br />
#150 Poster Board Number.....................................239<br />
COMPUTATIONAL BASED APPROACHES<br />
FOR IDENTIFYING AND UNDERSTANDING<br />
KINASES ASSOCIATED WITH<br />
CARDIOTOXICITY. D. Puppala 1 , V. Bonato 2 ,<br />
K. Leach 1 , S. Louise-May 1 , K. J. McConnell 3 , M.<br />
Gosink 4 and M. T. Pletcher 1 . 1 Compound Safety<br />
Prediction, Pfizer Inc., Groton, CT, 2 Biostatistics<br />
Group, Pfizer Inc., Groton, CT, 3 Computational<br />
Science CoE, Pfizer Inc., Groton, CT and 4 DSRD,<br />
Pfizer Inc., Groton, CT.<br />
#151 Poster Board Number.....................................240<br />
DISCOVERY OF NOVEL MICRO-RNAS<br />
FROM RAT LYMPHOCYTES DURING<br />
GLUCOCORTICOID INDUCED APOPTOSIS. <br />
R. Shah 1 , S. Vasa 1 , L. Smith 2 and J. Cidlowski 2 . 1 SRA<br />
International, Durham, NC and 2 National Institute<br />
<strong>of</strong> Environmental Health Science, Research Triangle<br />
Park, NC.<br />
#152 Poster Board Number.....................................241<br />
AUTOMATIC IN SILICO ASSESSMENT OF<br />
GENOTOXIC POTENTIAL IMPURITIES. A.<br />
Brigo, G. Gerebtz<strong>of</strong>f, M. Kansy, T. Weiser and T.<br />
Singer. Nonclinical Safety, F. H<strong>of</strong>fmann-La Roche<br />
Ltd., Basel, Switzerland.<br />
#153 Poster Board Number.....................................242<br />
AUTOMATED IDENTIFICATION OF<br />
STRUCTURE-TOXICITY RELATIONSHIPS<br />
USING ATOM SIGNATURES. L. Carlsson,<br />
E. Ahlberg Helgee and S. Boyer. Computational<br />
<strong>Toxicology</strong>, AstraZeneca, Mölndal, Sweden.<br />
#154 Poster Board Number.....................................243<br />
COMPUTATIONAL ASSESSMENT OF<br />
REACTIVE METABOLITE RISK IN DRUG<br />
DISCOVERY USING MECHANISTIC<br />
ENSEMBLE MODELLING. S. Boyer 1 , C.<br />
Hasselgren 1 , L. Peterlin-Masic 2 , O. Spjuth 3 and L.<br />
Carlsson 1 . 1 Computational <strong>Toxicology</strong>, AstraZeneca,<br />
Mölndal, Sweden, 2 Faculty <strong>of</strong> Pharmacy, University<br />
<strong>of</strong> Ljubljana, Ljubljana, Slovenia and 3 Department<br />
<strong>of</strong> Pharmaceutical Biosciences, Uppsala University,<br />
Uppsala, Sweden.<br />
#155 Poster Board Number.....................................244<br />
DESIGN AND DEVELOPMENT OF AN<br />
INSTITUTIONAL KNOWLEDGE-BASE<br />
AT FDA’S CENTER FOR FOOD SAFETY<br />
AND APPLIED NUTRITION. K. Arvidson, A.<br />
McCarthy, C. Yang and D. Hristozov. CFSAN, U.S.<br />
FDA, College Park, MD.<br />
#156 Poster Board Number.....................................245<br />
PHARMACOLOGICAL PROFILE<br />
SIMILARITY – A RELEVANT METHOD<br />
FOR ANTICIPATION OF IN VIVO SAFETY? <br />
D. Muthas 1 , M. Rolf 2 , S. Matis-Mitchell 3 and S.<br />
Boyer 1 . 1 Global Safety Assessment, AstraZeneca<br />
R&D, Mölndal, Sweden, 2 Global Safety Assessment,<br />
AstraZeneca R&D, Alderly Park, United Kingdom<br />
and 3 Discovery Information, AstraZeneca R&D,<br />
Wilmington, DE.<br />
128<br />
Education-Career Development Sessions<br />
Exhibitor Hosted Sessions<br />
Featured Sessions<br />
Historical Highlights<br />
Informational Sessions<br />
Platform Sessions